Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis by Yousef, G M et al.
Quantitative analysis of human kallikrein gene 14 expression in
breast tumours indicates association with poor prognosis
GM Yousef
1,2, CA Borgon ˜o
1,2, A Scorilas
3, R Ponzone
4, N Biglia
4, L Iskander
2, M-E Polymeris
2, R Roagna
4,
P Sismondi
4 and EP Diamandis*
,1,2
1Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada;
2Department of Laboratory Medicine and Pathobiology,
University of Toronto, Toronto, Ontario, Canada;
3National Center of Scientiﬁc Research ‘Demokritos’, IPC, Athens, 153 10, Greece;
4Academic Division
of Gynecological Oncology, University of Turin, Mauriziano Umberto Hospital and Institute for Cancer Research and Treatment (IRCC) of Candiolo, Turin,
Italy
KLK14 (formerly known as KLK-L6) is a recently identiﬁed member of the human kallikrein gene family. This family harbours
several genes aberrantly expressed in various cancers as well as established (PSA/hK3, hK2) and potential (hK6, hK10) cancer
markers. Similar to other kallikrein genes, KLK14 was found to be regulated by steroid hormones, particularly androgens and
progestins, in breast and ovarian cancer cell lines. Preliminary studies indicated that KLK14 is differentially expressed in breast,
ovarian, prostatic and testicular tumours. Given the above, we determined the prognostic signiﬁcance of KLK14 expression in
breast cancer. We studied KLK14 expression in 178 histologically conﬁrmed epithelial breast carcinomas by quantitative
reverse transcription–polymerase chain reaction and correlated with clinicopathological variables (tumour stage, grade,
histotype etc.) and with outcome (disease-free survival and overall survival), monitored over a median of 76 months. KLK14
mRNA levels ranged from 0 to 1219 arbitrary units in breast cancer tissues, with a mean+s.e. of 136+22. An optimal cutoff
value of 40.5 arbitrary units was selected, to categorise tumours as KLK14-positive or negative. Higher concentrations of
KLK14 mRNA were more frequently found in patients with advanced stage (III) disease (P=0.032). No statistically signiﬁcant
association was found between KLK14 and the other clinicopathological variables. KLK14 overexpression was found to be a
signiﬁcant predictor of decreased disease-free survival (hazard ratio of 2.31, P=0.001) and overall survival (hazard ratio of 2.21,
P=0.005). Cox multivariate analysis indicated that KLK14 was an independent prognostic indicator of disease-free survival and
overall survival. KLK14 also has independent prognostic value in subgroups of patients with a tumour size 42 cm and positive
nodal, oestrogen receptor and progestin receptor status. We conclude that KLK14 expression, as assessed by quantitative
reverse transcription–polymerase chain reaction, is an independent marker of unfavourable prognosis for breast cancer.
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Breast cancer is the most prevalent malignancy among women,
accounting for 21% of all female cancers and ranking third overall
when both sexes are considered (Parkin et al, 1999). Although the
increased use of screening for early disease diagnosis and the wide-
spread administration of systemic adjuvant therapies have lead to a
decline in mortality rates, breast cancer is still the leading cause of
death from cancer in women, causing over 39500 deaths in the US
annually (Peto et al, 2000; Jemal et al, 2002).
Given the heterogeneous nature of breast carcinomas, much
attention has been focussed on the identiﬁcation of tumour asso-
ciated molecular markers that reveal the biological proﬁle of each
tumour and ultimately aid in determining cancer risk, diagnosis,
screening, prognosis, monitoring, management and prediction of
therapeutic response in breast cancer patients (Duffy, 2001).
Among the multitude of markers discovered are serine proteases,
which participate in many aspects of carcinogenesis, including
stimulating cellular growth, angiogenesis and the degradation of
the extracellular matrix (Gottesman, 1990; Duffy, 1991). These
functions are in accord with clinical studies demonstrating that
the aberrant expression of certain serine proteases correlates with
the invasiveness and metastasis of cancer cells and predicts poor
prognosis in various malignancies (Herszenyi et al, 1999; Kuhn et
al, 1999).
Human kallikreins are a subset of secreted serine proteases
found in a wide range of tissues and biological ﬂuids and impli-
cated in diverse physiological and pathological processes
(Diamandis et al, 2000b; Yousef and Diamandis, 2001). The
kallikrein genes, denoted KLK1–KLK15, are located on chromo-
some 19q13.4 and encode for corresponding kallikrein enzymes,
hK1–hK15 (Diamandis et al, 2000a; Yousef et al, 2000b). Accumu-
lating evidence indicates that many members of this family are
differentially expressed in certain malignancies, including prostate
(Rittenhouse et al, 1998; Magklara et al, 1999; Barry, 2001; Yousef
et al, 2001c; Diamandis et al, 2002), testicular (Luo et al, 2001c),
breast (Yousef et al, 2000a,c) and ovarian (Anisowicz et al, 1996;
Diamandis et al, 2000c; Kim et al, 2001; Luo et al, 2001b; Magklara
et al, 2001; Obiezu et al, 2001; Yousef et al, 2001a) cancers. Also,
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hormone regulation, further suggesting a role for these enzymes
in endocrine-related tissues (Yousef and Diamandis, 2002). Addi-
tionally, PSA/hK3, is the best tumour marker available in clinical
medicine for diagnosing and managing prostate cancer (Diaman-
dis, 1998; Barry, 2001), hK2 is useful for certain subgroups of
prostate cancer patients (Magklara et al, 1999), hK6, 10 and 11,
have recently emerged as potential serological epithelial ovarian
cancer markers (Luo et al, 2001a; Diamandis et al, 2002), and
several others possess clinical utility as prognostic/predictive
markers (Diamandis and Yousef, 2001).
Human kallikrein gene 14 (KLK14), formerly known as KLK-L6,
is a recently identiﬁed member of the human kallikrein gene family
(Yousef et al, 2001b). Structurally, this gene is formed of ﬁve
coding exons and four intervening introns. The encoded protein,
hK14, is a trypsin-like serine protease, translated as an inactive
251 amino acid preproenzyme precursor of about 27.5 kDa, of
which 18 amino acids constitute the signal peptide and six amino
acids the activation peptide. hK14 harbours the conserved catalytic
triad characteristic of serine proteases and is highly homologous to
other kallikreins, including PSA/hK3. KLK14 has a restricted tissue
expression pattern and is found in the central nervous system as
well as in endocrine-related tissues such as the uterus, ovary,
thyroid and testis. Additionally, in situ hybridisation studies
demonstrated that KLK14 is expressed by the secretory epithelial
cells of benign prostate gland, prostatic intraepithelial neoplasia
and malignant prostate cells (Hooper et al, 2001). Preliminary
studies have shown that KLK14 is down-regulated at the mRNA
level in prostatic, testicular, ovarian and breast cancer tissues and
in two breast cancer cell lines (Yousef et al, 2001b). Hormonal
regulation studies in breast and ovarian cancer cell lines indicate
that KLK14 expression is controlled by the androgen receptor in
response to steroid hormones, particularly androgens and proges-
tins (our unpublished data). Based on these collective ﬁndings,
we hypothesised that KLK14 expression in malignant breast tissues
may have prognostic/predictive value for patients with breast carci-
nomas.
MATERIALS AND METHODS
Study population
Tumour specimens from 178 consecutive patients undergoing
surgical treatment for primary breast carcinoma at the Department
of Gynecologic Oncology, University of Turin, Turin, Italy were
analysed in this study. Patient age ranged from 25 to 87 years, with
a median of 58 years (Table 1). Follow-up information (median
follow-up period of 76 months) was available for 164 patients,
among whom 60 (36%) had relapsed and 51 (31%) died. All tissue
specimens were histologically conﬁrmed and frozen in liquid nitro-
gen immediately after surgery.
Clinical and pathological information documented at the time of
surgery included clinical stage, grade, histology and size of the
tumour, number of positive axillary nodes, steroid hormone recep-
tor status and treatment strategy (Table 2). Tumour sizes ranged
from 0.1 to 15 cm, with a median of 2.2 cm. Out of the 178
patients, 109 (61%) had ductal carcinoma, 28 (16%) lobular carci-
noma while 37 (21%) possessed other histological types. The
histotype was unknown for four patients. Patients with disease of
all three Stages (I–III) and tumour grades (I–III) were repre-
sented in this study, with staging determined according to the
TNM classiﬁcation and grading in accordance to the Bloom-
Richardson grading system (Bloom and Richardson, 1957). Oestro-
gen and progesterone receptor status was established as described
by the European Organization for Research and Treatment of
Cancer (EORTC, 1980). With respect to treatment, 33 (19%)
received no adjuvant treatment, 83 (47%) received tamoxifen,
while 59 (33%) received chemotherapy with or without tamoxifen.
This study has been approved by the Institutional Review Board of
the University of Turin.
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Table 2 Associations between KLK14 status
a and other variables in 178
patients with epithelial breast carcinomas
No. of patients (%)
Variable Total KLK14-negative KLK14-positive P value
Age (years)
545 34 22 (64.7) 12 (35.3)
45–55 46 34 (73.9) 12 (26.1) 0.63
d
455 95 64 (67.4) 31 (32.6)
X3
Menopausal status
Pre/peri 62 44 (71.0) 18 (29.0) 0.73
e
Post 113 76 (67.3) 37 (32.7)
X3
Tumor size (cm)
52 82 60 (73.2) 22 (26.8) 0.25
e
52 93 60 (64.5) 33 (35.5)
X3
Nodal status
Negative 67 51 (76.1) 16 (23.9) 0.17
e
Positive 93 61 (65.6) 32 (34.4)
X1 8
Stage
c
I 74 58 (78.4) 16 (21.6)
II 68 46 (67.6) 22 (32.4) 0.032
d
III 22 11 (50.0) 11 (50.0)
X1 4
Grade
b
I 72 48 (66.7) 24 (33.3)
II 51 36 (70.6) 15 (29.4) 0.89
e
III 49 33 (67.3) 16 (32.7)
X6
Histology
Ductal 109 73 (67.0) 36 (33.0)
Lobular 28 17 (60.7) 11 (39.3) 0.27
d
Other 37 29 (78.4) 8 (21.6)
X4
ER status
Negative 62 45 (72.6) 17 (27.4) 0.49
e
Positive 107 71 (66.4) 36 (33.6)
X9
PR status
Negative 78 52 (66.7) 26 (33.3) 0.74
e
Positive 92 64 (69.6) 28 (30.4)
X8
Adjuvant treatment
None 33 26 (78.8) 7 (21.2)
Tamoxifen 83 56 (67.5) 27 (32.5) 0.35
d
Chemotherapy+tamoxifen 59 38 (64.4) 21 (35.6)
X4
aCutoff point: 40.5, equals to 69
th percentile.
bBloom-Scarff-Richardson grading
system.
cTNM system.
dw
2 test.
eFisher’s Exact Test. X Status unknown.
Table 1 Distribution of numerical variables in the study
Variable No. of patients Mean+s.e.
a Median Range
KLK14 (arbitrary units) 178 136+22 4.28 0.00–1219
Age (years) 175 57.5+0.98 58.0 25–87
Tumour size (cm) 175 2.53+0.12 2.20 0.01–15.00
Lymph nodes
b 160 3.6+0.5 1 0–35
aSE, standard error.
bNumber of lymph nodes positive for malignancy.
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Tumour tissues were minced with a scalpel, on dry ice, and trans-
ferred immediately to 2 ml polypropylene tubes. They were then
homogenized and total RNA was extracted using Trizol
TM reagent
(Gibco–BRL) following the manufacturer’s instructions. The
concentration and purity of mRNA were determined spectrophoto-
metrically. Two mg of total RNA was reverse-transcribed into ﬁrst-
strand cDNA using the Superscript
TM pre-ampliﬁcation system
(Gibco–BRL). The ﬁnal volume was 20 ml.
Quantitative real-time polymerase chain reaction (PCR)
and continuous monitoring of PCR products
Based on the published genomic sequence of KLK14 (GenBank
accession #AF161221), two gene-speciﬁc primers were designed
(6F5: 5'-AGT GGG TCA TCA CTG CTG CT-3' and 6R5: 5'-TCG
TTT CCT CAA TCC AGC TT-3'). These primers spanned more
than two exons to avoid contamination by genomic DNA.
Real-time monitoring of PCR reaction was performed using the
LightCycler
TM system (Roche Molecular Systems, Indianapolis,
USA) and the SYBR green I dye, which binds preferentially to
double-stranded DNA. Fluorescence signals are proportional to
the concentration of the product and are measured at the end of
each cycle and immediately displayed on a computer screen,
permitting real time monitoring of the PCR reaction. The reaction
is characterised at the point during cycling when ampliﬁcation of
PCR products is ﬁrst detected, rather than the amount of PCR
product accumulated after a ﬁxed number of cycles. The higher
the starting quantity of the template, the earlier a signiﬁcant
increase in ﬂuorescence is observed. The threshold cycle is deﬁned
as the fractional cycle number at which ﬂuorescence passes a ﬁxed
threshold above baseline.
Endogenous control
For each sample, the amount of KLK14 cDNA and of an endogen-
ous control (b actin, a housekeeping gene) were determined using
a calibration curve (see below). The amount of KLK14 was then
divided by the amount of the endogenous reference, to obtain a
normalised KLK14 value.
Standard curve construction
The full-length mRNA sequence of the KLK14 gene was ampliﬁed
by PCR using gene-speciﬁc primers, and the PCR product was
cloned into a TOPO TA cloning vector (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. A plasmid
containing b-actin cDNA, was similarly prepared. Plasmids were
puriﬁed using a mini-prep kit (Qiagen Inc., Valencia, CA, USA).
Different standard curves for actin and KLK14 were constructed
using serial dilutions of the plasmid. These standards were included
in each run. The LightCycler software automatically calculates the
standard curve by plotting the starting dilution of each standard
sample vs the threshold cycle, and the sample concentrations are
then calculated accordingly. Standards for both KLK14 and actin
RNAs were deﬁned to contain an arbitrary starting concentration,
since no primary preparations exist. Hence, all calculated concen-
trations are relative to the concentration of the selected standard.
Each sample was repeated twice to ensure reproducibility.
PCR ampliﬁcation
The PCR reaction was carried out on the LightCycle
TM system. For
each run, a master mixture was prepared on ice, containing 1 mlo f
cDNA, 2 ml of LC DNA Master SYBR Green 1 mix, 50 ng of
primers and 1.2 mlo f2 5m M MgCl2. After the reaction mixture
was loaded into the glass capillary tube, the cycling conditions were
carried out as shown in Table 3.
Melting curve
For distinguishing speciﬁc from non-speciﬁc products and primer
dimers, a melting curve was obtained after ampliﬁcation by hold-
ing the temperature at 708C for 30 s followed by a gradual increase
in temperature to 988C at a rate of 0.28C per s, with the signal
acquisition mode set at step. To verify the melting curve results,
representative samples of the PCR products were run on 1.5%
agarose gels, puriﬁed, and cloned into the pCR 2.1-TOPO vector
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. The inserts were sequenced from both directions
using vector-speciﬁc primers with an automated DNA sequencer.
Statistical analysis
Patients were subdivided into groups based on different clinical or
pathologic parameters (Table 2) and statistical analyses were
performed using SAS software (SAS Institute, Cary, NC, USA).
An optimal cutoff value was deﬁned by w
2 analysis based on the
ability of KLK14 values to predict the disease-free survival (DFS)
and overall survival (OS) of the study population. According to
this value, tumours were categorised as KLK14-positive or
KLK14-negative and associations between KLK14 status and other
qualitative variables were analysed using the w
2 or the Fisher’s
Exact test, where appropriate. The cutoff value for tumour size
was 2 cm. Lymph node status was either positive (any positive
number of nodes) or negative. Age was categorised into three
groups: less than 45 years, 45–55 years and greater than 55 years.
Survival analyses were performed by constructing Kaplan–Meier
disease free survival (DFS) and overall survival (OS) curves and
differences between curves were evaluated by the log-rank test
(Mantel, 1966), as well as by estimating the relative risks for relapse
and death using the Cox proportional hazards regression model
(Cox, 1972). Cox analysis was conducted at both univariate and
multivariate levels. Only patients for whom the status of all vari-
ables was known were included in the multivariate regression
models, which incorporated KLK14 and all other variables for
which the patients were characterised. The multivariate models
were adjusted for KLK14 expression in tumours, patient age,
tumour size, stage, grade, histological type and oestrogen receptor
(ER) and progestin receptor (PR) status.
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Table 3 Experimental protocol used for quantitative PCR ampliﬁcation
of the KLK14 gene
Segment Temperature Hold time Slope Application
number target (8C) (s) (8C/s) mode
Program: Denaturation Cycles: 1
1 95 600 20 None
Program: PCR Cycles: 35
1 95 0 20 None
2 62 5 20 None
3 72 40 20 None
4 85 5 20 Single
Program: Melting Cycles: 1
1 95 0 20 None
2 72 30 20 None
3 97 0 0.2 Step
Program: Cooling Cycles: 1
1 40 30 1 None
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Relationship between KLK14 expression and other
parameters
KLK14 mRNA levels ranged from 0 to 1219 arbitrary units in
breast cancer tissues, with a mean+s.e. of 136+22. The cutoff
point (40.5 arbitrary units; 69th percentile) indicated that 55
(31%) of the 178 breast tumour tissues were positive for KLK14
expression (Figure 1). Table 2 depicts the distribution of KLK14
expression, positive or negative, in breast tumour tissues in relation
to other established prognostic factors such as menopausal status,
tumour size, stage, grade, histological type, nodal status, steroid
receptor status and adjuvant therapy. Patients with KLK14-positive
breast tumours more frequently had advanced stage (III) disease
(P=0.032). Signiﬁcant associations between KLK14 expression and
tumour size, grade and histology, or menopausal, nodal and
steroid receptor status were not observed.
Univariate and multivariate survival analysis
The strength of association between each clinicopathological vari-
able and DFS and OS is displayed in Table 4. In univariate
analysis, patients with KLK14-positive tumours had a signiﬁcantly
increased risk of relapse (decreased DFS) and death (decreased
OS) (hazards ratios of 2.31 and 2.21; P=0.001 and 0.005, respec-
tively). Importantly, when treated as a continuous variable,
KLK14 expression retained its statistically signiﬁcant association
with decreased DFS and OS (P50.001). Further, when survival
outcomes were adjusted for all other variables in the multivariate
analysis (i.e. Cox proportional hazard regression model), the
adverse effects of KLK14 positivity on DFS and OS were preserved
(hazards ratios of 2.14 and 1.99; P=0.009 and 0.029, respectively),
implying that KLK14 expression is an independent prognostic indi-
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Figure 1 Determination of the optimal cutoff value for KLK14
expression. For details, see text.
Table 4 Univariate and multivariate analysis of KLK14 expression in relation to DFS and OS
Disease-free survival (DFS) Overall survival (OS)
KLK14 status HR
a 95% CI
b P value HR
a 95% CI
b P value
Univariate analysis (n=164)
Categorical variable
c
Negative 1.00 1.00
Positive 2.31 1.39–3.85 0.001 2.21 1.27–3.83 0.005
Continuous variable 1.001 1.00–1.002 50.001 1.001 1.00–1.002 50.001
Multivariate analysis
d(n=148)
Categorical variable
c
Negative 1.00 1.00
Positive 2.14 1.21–3.80 0.009 1.99 1.07–3.70 0.029
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConﬁdence interval of the estimated HR.
cKLK14 status based on a cutoff point equal to the 69
th percentile of the distribution of KLK14 values.
dMultivariate models
were adjusted for lymph node status, tumour size, patient age, grade, histologic type, ER and PR expression.
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Figure 2 Kaplan–Meier survival curves for disease-free survival (A) and
overall survival (B) in patients with KLK14-positive and negative breast
tumours. n=number of samples.
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demonstrate that patients with KLK14-positive tumours have
shorter DFS (P50.001) and OS (P=0.004) compared to those
who are KLK14-negative.
Univariate and multivariate survival analysis in
subgroups of patients
We further examined the associations between KLK14 expression
levels and survival outcomes in subgroups of patients stratiﬁed
by tumour size, nodal, OR and PR status (Table 5). KLK14 expres-
sion signiﬁcantly impacted survival in subgroups of patients with a
tumour size 42 cm and positive nodal, OR and PR status.
Univariate analysis revealed that KLK14-positive patients with a
tumour size 42 cm were about three times more likely to suffer
disease progression and four times more likely to die than
KLK14-negative patients (P=0.004 and 0.007, respectively). These
survival differences remained signiﬁcant after the data were
subjected to multivariate analysis (P=0.021 and 0.014, respectively).
Among patients with positive nodal status, high KLK14 expression
was associated with approximately two-fold greater risk of relapse
and death in both univariate (P=0.007 and 0.017, respectively)
and multivariate analyses (P=0.010 and 0.025, respectively). Simi-
larly, there was a tendency for an increased risk of disease
progression and death in both OR and PR positive patients with
KLK14-positive tumours. In univariate analysis, hazard ratios
derived from the Cox regression model in relation to DFS and
OS were 3.40 (P=0.001) and 3.47 (P=0.004) respectively, for ER
positive and 3.61 (P=0.001) and 3.17 (P=0.014) for PR positive
patients. Under multivariate analysis, KLK14 retained its indepen-
dent prognostic value in these subgroups of patients.
DISCUSSION
The optimal management of women with breast cancer involves
a multidisciplinary approach, including the use of biological
markers. Ultimately, the goal is to select the best marker or
panel of markers that are most informative in terms of their
ability to predict relapse, disease progression, survival and
response to therapy. Traditional prognostic/predictive factors in
breast cancer include tumour size, grade, nodal status, hormone
receptor status, vascular invasion and age (Denley et al, 2001).
However, only hormone receptor status has predictive value in
selecting patients who are likely to respond to therapy, and is
the only marker recommended for routine use by the American
Society of Clinical Oncology (Smith et al, 2001) and the College
of American Pathologists Consensus Statement (Fitzgibbons et al,
2000).
Many other potential biological markers have been identiﬁed as
prognostic factors including p53, c-myc, BCL-2, HER-2, vascular
endothelial growth factor (VEGF), urokinase plasminogen activator
(uPA), CA 15-3, BR 27.29 and cathepsin B and D (Maguire et al,
1998; Duffy et al, 1999; Scorilas et al, 1999; Hamilton and Piccart,
2000; Bundred, 2001). Some markers are also predictive. For
instance, expression of HER-2 has value in determining response
to treatment and in selecting patients for Herceptin therapy (Ross
and Fletcher, 1998). The multitude of new candidate biomarkers
will likely lead to insights into the cellular changes that correlate
with, or determine the different biological properties and diverse
behaviour of individual breast tumours. Furthermore, stratifying
patients based on the presence or absence of such markers may
help to tailor different therapeutic strategies to meet individual
needs (Clark et al, 1994).
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Table 5 Associations between KLK14 and DFS and OS in subgroups of patients stratiﬁed by tumour size, nodal
status, oestrogen and progesterone receptor status
Disease-free survival (DFS) Overall survival (OS)
Variable HR
a 95% CI
b P value HR
a 95% CI
b P value
Tumor size 42cm (n=79)
KLK14 unadjusted 3.48 1.47–8.29 0.004 4.13 1.47–11.64 0.007
KLK14 adjusted
c 3.52 1.22–11.31 0.021 6.26 1.46–26.87 0.014
Tumor size 42cm (n=85)
KLK14 unadjusted 1.66 0.88–3.13 0.11 1.51 0.77–2.92 0.22
KLK14 adjusted
c 1.58 0.77–4.09 0.17 1.90 0.84–4.27 0.12
Node negative (n=65)
KLK14 unadjusted 2.27 0.64–8.06 0.20 1.51 0.27–8.24 0.63
KLK14 adjusted
d 2.01 0.46–8.71 0.35 1.89 0.29–12.15 0.49
Node positive (n=88)
KLK14 unadjusted 2.24 1.24–4.06 0.007 2.12 1.14–3.95 0.017
KLK14 adjusted
d 2.31 1.21–4.34 0.010 2.13 1.09–4.14 0.025
ER negative (n=59)
KLK14 unadjusted 1.83 0.84–3.98 0.12 1.97 0.90–4.33 0.087
KLK14 adjusted
e 0.89 0.33–2.34 0.82 0.92 0.33–2.52 0.88
ER positive (n=99)
KLK14 unadjusted 3.40 1.65–6.99 0.001 3.47 1.49–8.05 0.004
KLK14 adjusted
e 3.14 1.26–7.79 0.014 2.88 1.01–8.18 0.047
PR negative (n=72)
KLK14 unadjusted 1.68 0.85–3.34 0.13 1.83 0.91–3.69 0.088
KLK14 adjusted
f 1.27 0.59–2.74 0.53 1.31 0.06–2.89 0.49
PR positive (n=87)
KLK14 unadjusted 3.61 1.63–7.97 0.001 3.17 1.25–8.06 0.014
KLK14 adjusted
f 6.04 2.19–16.61 0.001 4.45 1.37–14.39 0.012
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConﬁdence interval of the estimated HR.
cMultivariate
models were adjusted for tumor grade, nodal status, ER, PR, histologic type and age.
dMultivariate models were adjusted for tumour size,
grade, ER, PR, histologic type and age.
eMultivariate models were adjusted for tumour size, grade, nodal status, PR, histologic type and
age.
fMultivariate models were adjusted for tumour size, grade, nodal status, ER, histologic type and age.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1287–1293In this paper, we identify KLK14 as a new independent marker
of unfavourable prognosis in breast cancer. Patients with KLK14-
positive breast tumours were more likely to have advanced stage
(III) disease. When assessing KLK14 expression in terms of predict-
ing survival outcomes, we found an increased risk of relapse and
death for patients with KLK14-positive tumours. This was also
observed in subgroups of patients with a tumour size 42 cm,
positive nodal, OR and PR status. Hence, KLK14 expression may
aid in predicting relapse, disease progression and/or survival in
breast cancer patients.
Interestingly, the results obtained for KLK14 in this study are
comparable to those obtained for KLK3, KLK6 and KLK15 in
breast cancer (Yu et al, 1995; Anisowicz et al, 1996) and KLK4,
KLK5 and KLK10 in ovarian cancer (Kim et al, 2001; Luo et al,
2001b; Obiezu et al, 2001), in that high expression of these kallik-
rein genes also correlated with patient prognosis. Similar to KLK14,
these genes are also under steroid hormone regulation (Yousef and
Diamandis, 2001). These observations allow us to speculate that
multiple kallikreins may participate in a common enzymatic path-
way that plays a role in the normal physiology of the breast. This
pathway may be deregulated in breast carcinogenesis. As is the case
with many other serine proteases, certain kallikreins may degrade
the extracellular matrix promoting tumour invasiveness and
metastasis.
It was recently realised that KLK14 is under steroid hormone
regulation, particularly androgens and progestins, and that these
effects are mediated through the androgen receptor (our unpub-
lished data). It is also known that breast cancer is a hormone-
dependent malignancy (Russo and Russo, 1998) and that androgen
receptors are present in 70–90% of primary breast tumours
(Soreide et al, 1992), and 75% of breast cancer metastases (Lea
et al, 1989). Thus, it is likely that the androgen receptor, acting
as a ligand-activated transcription factor, upregulates KLK14 gene
expression during breast carcinogenesis.
The role of androgens in the aetiology of breast cancer is
ill-deﬁned. In vitro, they both stimulate (MCF-7, MDA-453) or
inhibit (T-47D, ZR-75-1, MFM-223) the growth of AR-positive
breast cancer cell lines (Hackenberg et al, 1991; Birrell et al,
1995). Animal studies have demonstrated that androgens shorten
the latency period, enhance tumour size and increase the incidence
of breast tumours, by promoting rather than initiating carcino-
genesis in rodents (Liao et al, 1998; Xie et al, 1999). These effects
may be mediated by androgen-regulated genes that directly func-
tion in cell growth regulation and through interaction of the AR
with other transcription regulators, allowing for cross-talk with
other growth pathways (Brys, 2000). Thus, the identiﬁcation of
androgen regulated genes, such as KLK14, may help to deﬁne
new targets for breast cancer treatment. Such new treatments
may be particularly important in metastatic disease, where the
AR is often the sole steroid receptor expressed.
In summary, we quantiﬁed KLK14 expression in breast tumours
and found that high KLK14 expression is associated with decreased
DFS and OS in both univariate and multivariate analysis. Addi-
tional basic and clinical studies are required to delineate the
activity of KLK14 in both the normal and malignant breast and
to further deﬁne the clinical value of this biomarker.
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